Selection of chemotherapy for glioblastoma expressing O6-methylguanine-DNA methyltransferase

Iwadate,Yasuo; Matsutani,Tomoo; Hasegawa,Yuzo; Shinozaki,Natsuki; Oide,Takashi; Tanizawa,Toru; Nakatani,Yukio; Saeki,Naokatsu; Fujimoto,Shuichi

doi:10.3892/etm_00000009

Selection of chemotherapy for glioblastoma expressing O6-methylguanine-DNA methyltransferase

Authors:
- Yasuo Iwadate
- Tomoo Matsutani
- Yuzo Hasegawa
- Natsuki Shinozaki
- Takashi Oide
- Toru Tanizawa
- Yukio Nakatani
- Naokatsu Saeki
- Shuichi Fujimoto
View Affiliations

Affiliations: Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan. iwadatey@faculty.chiba-u.jp
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000009
Pages: 53-57

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The therapeutic benefit of nitrosoureas or temozolomide for glioblastoma is limited mainly by O6-methylguanine-DNA methyltransferase (MGMT) expression. The aim of this study was to evaluate the effectiveness of various anticancer drugs for MGMT-positive glioblastoma. Seventy-four glioblastoma patients were administered various anticancer drugs according to drug sensitivity testing. For the individualization, drug-induced apoptosis was quantified by flow cytometry in the primary culture of surgically resected tumor cells. The MGMT protein expression was analyzed by immunohistochemistry. The median survival of the patients receiving the individualized chemotherapy was 19.4 months (95% CI, 15.9-22.1). The patients with negative MGMT immunostaining had significantly longer survival than those with positive MGMT immunostaining [median survival, 22.3 months (95% CI, 17.6-27.0) vs. 15.1 months (95% CI, 13.4-16.8); p=0.0188]. For MGMT-positive tumors, the platinum agents and the taxanes were more frequently selected for administration than the other categories of anticancer agents. The patient survival period of MGMT-positive glioblastomas treated with the platinum agents or the taxanes [median survival, 20.1 months (95% CI, 18.0-22.7)] was significantly longer than that of MGMT-positive tumors treated with nitrosoureas (p=0.0026), and was equivalent to that of MGMT-negative glioblastomas (p=0.3047). These results suggest that the platinum agents and the taxanes offer the best probability to be effective against immunohistochemically MGMT-positive glioblastomas.

View Figures

View References

1.	Shapiro WR: Current therapy for brain tumors: back to the future. Arch Neurol. 56:429–432. 1999. View Article : Google Scholar : PubMed/NCBI
2.	Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol. 19:509–518. 2001.PubMed/NCBI
3.	Glioma Meta-analysis Trialist (GMT) Group: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 359:1011–1018. 2002. View Article : Google Scholar : PubMed/NCBI
4.	Stupp R, Mason WP, van den Bent MJ, et al: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar
5.	Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Jaeckle KA, Eyre HJ, Townsend JJ, et al: Correlation of tumor O⁶-alkylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 16:3310–3315. 1998.
7.	Esteller M, Garcia-Foncillas J, Andion E, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000. View Article : Google Scholar
8.	Brell M, Tortosa A, Verger E, et al: Prognostic significance of O⁶-alkylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplatic gliomas. Clin Cancer Res. 11:5167–5174. 2005.
9.	Chinot OL, Barrie M, Fuentes S, et al: Correlation between O⁶-alkylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 25:1470–1475. 2007.PubMed/NCBI
10.	Cortazar P and Johnson BE: Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol. 17:1625–1631. 1999.PubMed/NCBI
11.	Alonso K: Human tumor stem cell assay. A prospective clinical trial. Cancer. 54:2475–2479. 1984. View Article : Google Scholar : PubMed/NCBI
12.	Von Hoff DD, Sandbach JF, Clark GM, et al: Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst. 82:110–116. 1990.PubMed/NCBI
13.	Gazdar AF, Steinberg SM, Russell EK, et al: Correlation of in vitro drug-sensitivity testing with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst. 82:117–124. 1990. View Article : Google Scholar : PubMed/NCBI
14.	Cortazar P, Gazdar AF, Woods E, et al: Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin Cancer Res. 3:741–747. 1997.PubMed/NCBI
15.	Iwadate Y, Fujimoto S, Namba H and Yamaura A: Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing. Br J Cancer. 89:1896–1900. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Iwadate Y, Fujimoto S, Sueyoshi K, et al: Prediction of drug cytotoxicity in 9L rat brain tumor by using flow cytometry with a deoxyribonucleic acid-binding dye. Neurosurgery. 40:782–788. 1997. View Article : Google Scholar : PubMed/NCBI
17.	Iwadate Y, Fujimoto S and Yamaura A: Differential chemosensitivity in human intracerebral gliomas measured by flow cytometric DNA analysis. Int J Mol Med. 10:187–192. 2002.PubMed/NCBI
18.	Alberts DS and Chen HSG: Tabular Summary of Pharmacokinetic Parameters Relevant to In Vitro Drug Assay. Alan R. Liss. New York: 351–359. 1980.
19.	Higuchi Y, Iwadate Y and Yamaura A: Treatment of low-grade oligodendroglial tumors without radiotherapy. Neurology. 63:2384–2386. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Iwadate Y, Namba H and Sueyoshi K: Intra-arterial ACNU and cisplatin chemotherapy for the treatment of glioblastoma multiforme. Neurol Med Chir. 35:598–603. 1995. View Article : Google Scholar : PubMed/NCBI
21.	Mason WP and Cairncross JG: Drug insight: temozolomide as a treatment for malignant glioma – impact of a recent trial. Nat Clin Pract Neurol. 1:88–95. 2005.
22.	Tanaka S, Kobayashi I, Utsuki S, Oka H, Yasui Y and Fujii K: Down-regulation of O⁶-methylguanine-DNA methyltransferase gene expression in gliomas by platinum compounds. Oncol Rep. 14:1275–1280. 2005.
23.	Beith J, Hartley J, Darling J and Souhami R: DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioblastoma cell lines which vary in cellular concentration of O⁶-alkylguanine-DNA methyltransferase. Br J Cancer. 75:500–505. 1997. View Article : Google Scholar : PubMed/NCBI
24.	Preuss I, Thust R and Kaina B: Protective effect of O⁶-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinigenic activity of different antineoplastic drugs. Int J Cancer. 65:506–512. 1996.
25.	Fruehauf JP, Brem H, Parker R, et al: In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res. 12:4523–4532. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Balana C, Ramirez JL, Rosell R, et al: O⁶-methylguanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolomide plus cisplatin in glioblastoma multiforme. Clin Cancer Res. 9:1461–1468. 2003.
27.	Watanabe T, Katayama Y, Ogino A, et al: Preliminary individualized chemotherapy for malignant astrocytomas based on O⁶-methylguanine-deoxyribonucleic acid methyltransferase methylation analysis. Neurol Med Chir. 46:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
28.	Silvani A, Eoli M, Salmaggi A, et al: Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J Neurooncol. 66:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
29.	Rosenthal MA, Gruber ML, Glass J, et al: Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 47:59–63. 2000. View Article : Google Scholar : PubMed/NCBI
30.	Langer CJ, Ruffer J, Rhodes H, et al: Phase II Radiation Therapy Oncology Group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 51:113–119. 2001. View Article : Google Scholar
31.	Ashamalla H, Zaki B, Mokhtar B, et al: Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. Technol Cancer Res Treat. 6:169–176. 2007. View Article : Google Scholar
32.	Karmakar S, Banik NL and Ray SK: Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human gliobastoma U87MG xenografts in nude mice. Cancer. 112:596–607. 2008. View Article : Google Scholar : PubMed/NCBI
33.	Friedman HS, McLendon RE, Kerby T, et al: DNA mismatch repair and O⁶-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 16:3851–3857. 1998.PubMed/NCBI
34.	Mollemann M, Wolter M, Feisberg J, et al: Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer. 113:379–385. 2005. View Article : Google Scholar : PubMed/NCBI